Cargando…

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2

The type II transmembrane serine protease TMPRSS2 facilitates the entry of coronaviruses, such as SARS-CoV-2, into host cells by cleaving the S(1)/S(2) interface of the viral spike protein. Based on structural data derived from X-ray crystallographic data of related trypsin-like proteases, a homolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escalante, Diego E., Ferguson, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862521/ https://www.ncbi.nlm.nih.gov/pubmed/33564221 http://dx.doi.org/10.1007/s00044-021-02708-7

Ejemplares similares

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs
por: Wu, Tong, et al.
Publicado: (2022)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Hoffmann, Markus, et al.
Publicado: (2020)

Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges
por: Mahmoud, Ismail Sami, et al.
Publicado: (2021)

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Djomkam, Alexandra Lindsey Zune, et al.
Publicado: (2020)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2020)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2021)

Host Serine Proteases TMPRSS2 and TMPRSS11D Mediate Proteolytic Activation and Trypsin-Independent Infection in Group A Rotaviruses
por: Sasaki, Michihito, et al.
Publicado: (2021)

Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L
por: Prasad, Kartikay, et al.
Publicado: (2021)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2022)

Exploring the phytochemicals of Platycodon grandiflorus for TMPRSS2 inhibition in the search for SARS-CoV-2 entry inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2022)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease
por: Stevaert, Annelies, et al.
Publicado: (2022)

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
por: Ou, Tianling, et al.
Publicado: (2021)

Trypsin enhances SARS-CoV-2 infection by facilitating viral entry
por: Kim, Yeeun, et al.
Publicado: (2022)

Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases
por: Ferguson, Timothy E. G., et al.
Publicado: (2022)

Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19
por: Yamazaki, Emiko, et al.
Publicado: (2023)

Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease
por: Kreutzberger, Alex J. B., et al.
Publicado: (2021)

Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease
por: Kreutzberger, Alex J.B., et al.
Publicado: (2021)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
por: Qiao, Yuanyuan, et al.
Publicado: (2021)

BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry
por: Moumbock, Aurélien F. A., et al.
Publicado: (2022)

The Transmembrane Protease Serine 2 (TMPRSS2) Non-Protease Domains Regulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike-Mediated Virus Entry
por: Strobelt, Romano, et al.
Publicado: (2023)

In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)
por: Barge, Sagar, et al.
Publicado: (2021)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint
por: Kaur, Taruneet, et al.
Publicado: (2021)

Antiandrogens Target TMPRSS2 and Reduce SARS-CoV-2 Virus Entry in Lung Cells
por: Leach, Damien A, et al.
Publicado: (2021)

NSP16 promotes the expression of TMPRSS2 to enhance SARS-CoV-2 cell entry
por: Han, Tianyu, et al.
Publicado: (2022)

TMPRSS2: An Equally Important Protease as ACE2 in the Pathogenicity of SARS-CoV-2 Infection
por: Parmar, Malvinder S.
Publicado: (2021)

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection
por: Maggio, Roberto, et al.
Publicado: (2020)

Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract
por: Liu, Yichuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ctmetkraelf3dskrkovba5jip